Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Acute Coronary Syndrome | 30 | 2023 | 2261 | 5.900 |
Why?
|
Ticlopidine | 13 | 2022 | 878 | 2.700 |
Why?
|
Myocardial Infarction | 33 | 2023 | 11416 | 2.260 |
Why?
|
Anticholesteremic Agents | 7 | 2022 | 966 | 2.220 |
Why?
|
Platelet Aggregation Inhibitors | 23 | 2022 | 3000 | 2.120 |
Why?
|
Lipoprotein(a) | 6 | 2022 | 397 | 2.010 |
Why?
|
Benzaldehydes | 8 | 2018 | 65 | 1.940 |
Why?
|
Oximes | 8 | 2018 | 318 | 1.720 |
Why?
|
Purinergic P2Y Receptor Antagonists | 5 | 2022 | 348 | 1.710 |
Why?
|
Pyridines | 11 | 2021 | 2864 | 1.650 |
Why?
|
Hemorrhage | 11 | 2022 | 3265 | 1.410 |
Why?
|
Atherosclerosis | 7 | 2023 | 3243 | 1.310 |
Why?
|
Heart Failure | 23 | 2023 | 10190 | 1.250 |
Why?
|
Angina, Unstable | 5 | 2020 | 930 | 1.210 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 9 | 2022 | 3130 | 1.160 |
Why?
|
Imines | 4 | 2012 | 35 | 1.110 |
Why?
|
Cyclopropanes | 2 | 2016 | 418 | 1.020 |
Why?
|
Thiophenes | 5 | 2013 | 602 | 1.010 |
Why?
|
Double-Blind Method | 22 | 2022 | 11913 | 1.000 |
Why?
|
Women | 3 | 2021 | 226 | 0.990 |
Why?
|
Sex Characteristics | 5 | 2022 | 2544 | 0.980 |
Why?
|
Natriuretic Peptide, Brain | 11 | 2023 | 1579 | 0.980 |
Why?
|
Cardiovascular Diseases | 18 | 2023 | 14381 | 0.960 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 3 | 2021 | 728 | 0.930 |
Why?
|
Coronary Artery Disease | 12 | 2020 | 6312 | 0.860 |
Why?
|
Guilt | 1 | 2022 | 96 | 0.850 |
Why?
|
Stroke | 12 | 2023 | 9485 | 0.820 |
Why?
|
Coronary Restenosis | 2 | 2021 | 426 | 0.820 |
Why?
|
Early Termination of Clinical Trials | 1 | 2021 | 69 | 0.820 |
Why?
|
Calgranulin A | 1 | 2021 | 82 | 0.810 |
Why?
|
Calgranulin B | 1 | 2021 | 87 | 0.800 |
Why?
|
1-Alkyl-2-acetylglycerophosphocholine Esterase | 5 | 2018 | 128 | 0.800 |
Why?
|
Lactones | 3 | 2019 | 337 | 0.790 |
Why?
|
Phospholipases A | 2 | 2014 | 218 | 0.760 |
Why?
|
Platelet Function Tests | 2 | 2021 | 267 | 0.740 |
Why?
|
Judgment | 1 | 2022 | 287 | 0.730 |
Why?
|
Pravastatin | 2 | 2014 | 392 | 0.690 |
Why?
|
Heptanoic Acids | 2 | 2014 | 352 | 0.690 |
Why?
|
P-Selectin | 1 | 2021 | 616 | 0.690 |
Why?
|
Piperazines | 5 | 2013 | 2541 | 0.660 |
Why?
|
Glucosides | 1 | 2021 | 374 | 0.650 |
Why?
|
Drug Therapy | 1 | 2021 | 517 | 0.650 |
Why?
|
Thrombolytic Therapy | 6 | 2013 | 2157 | 0.650 |
Why?
|
Proton Pump Inhibitors | 3 | 2013 | 478 | 0.640 |
Why?
|
Cystatin C | 1 | 2018 | 247 | 0.640 |
Why?
|
Fatty Acid-Binding Proteins | 3 | 2013 | 317 | 0.640 |
Why?
|
Receptors, Thrombin | 3 | 2014 | 137 | 0.640 |
Why?
|
Glomerular Filtration Rate | 6 | 2022 | 2104 | 0.640 |
Why?
|
Secondary Prevention | 7 | 2019 | 1510 | 0.630 |
Why?
|
Hypercholesterolemia | 2 | 2022 | 1173 | 0.630 |
Why?
|
Drug-Eluting Stents | 2 | 2021 | 718 | 0.590 |
Why?
|
CD40 Ligand | 2 | 2021 | 532 | 0.580 |
Why?
|
Benzhydryl Compounds | 1 | 2021 | 712 | 0.550 |
Why?
|
Diabetic Angiopathies | 3 | 2016 | 844 | 0.540 |
Why?
|
Peptide Fragments | 9 | 2023 | 5155 | 0.540 |
Why?
|
Death, Sudden, Cardiac | 3 | 2021 | 1501 | 0.540 |
Why?
|
Galectin 3 | 2 | 2016 | 217 | 0.530 |
Why?
|
Sleep Disorders, Circadian Rhythm | 1 | 2017 | 232 | 0.530 |
Why?
|
Risk Assessment | 16 | 2021 | 23493 | 0.530 |
Why?
|
Fatty Acids, Omega-3 | 2 | 2021 | 1278 | 0.530 |
Why?
|
Humans | 112 | 2023 | 716923 | 0.520 |
Why?
|
Platelet Activation | 4 | 2016 | 654 | 0.510 |
Why?
|
Treatment Outcome | 32 | 2022 | 62172 | 0.500 |
Why?
|
Aspirin | 5 | 2022 | 3167 | 0.500 |
Why?
|
Adenosine Monophosphate | 1 | 2016 | 274 | 0.500 |
Why?
|
Coronary Disease | 4 | 2018 | 6128 | 0.490 |
Why?
|
Pyrroles | 2 | 2014 | 1186 | 0.490 |
Why?
|
Randomized Controlled Trials as Topic | 12 | 2021 | 9561 | 0.480 |
Why?
|
Female | 76 | 2022 | 377705 | 0.470 |
Why?
|
RNA, Small Interfering | 1 | 2022 | 3623 | 0.470 |
Why?
|
Male | 71 | 2022 | 351000 | 0.470 |
Why?
|
Cardiovascular Agents | 2 | 2021 | 839 | 0.460 |
Why?
|
Blood Proteins | 2 | 2016 | 1140 | 0.460 |
Why?
|
Cholesterol, LDL | 7 | 2022 | 2374 | 0.460 |
Why?
|
Acetates | 1 | 2014 | 309 | 0.460 |
Why?
|
Dyspnea | 8 | 2008 | 1257 | 0.450 |
Why?
|
Ischemia | 1 | 2021 | 1913 | 0.450 |
Why?
|
Blood Platelets | 5 | 2017 | 2476 | 0.440 |
Why?
|
Thiazoles | 2 | 2021 | 1515 | 0.440 |
Why?
|
Fibroblast Growth Factors | 1 | 2018 | 887 | 0.440 |
Why?
|
Middle Aged | 54 | 2022 | 214874 | 0.440 |
Why?
|
Risk Factors | 32 | 2023 | 70808 | 0.430 |
Why?
|
Phospholipases A2, Secretory | 1 | 2011 | 33 | 0.430 |
Why?
|
Electrocardiography | 4 | 2021 | 6402 | 0.430 |
Why?
|
Thrombosis | 2 | 2022 | 2848 | 0.430 |
Why?
|
Communication Barriers | 1 | 2014 | 380 | 0.430 |
Why?
|
Aged | 49 | 2022 | 162670 | 0.420 |
Why?
|
Interleukin-18 | 1 | 2012 | 251 | 0.410 |
Why?
|
Angioplasty, Balloon, Coronary | 3 | 2009 | 1862 | 0.400 |
Why?
|
Adenosine | 1 | 2015 | 824 | 0.400 |
Why?
|
Calcium Channel Blockers | 1 | 2013 | 700 | 0.390 |
Why?
|
Receptor, PAR-1 | 3 | 2019 | 114 | 0.390 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2011 | 262 | 0.370 |
Why?
|
Myocardial Revascularization | 3 | 2016 | 846 | 0.370 |
Why?
|
Purinergic P2 Receptor Antagonists | 1 | 2009 | 72 | 0.370 |
Why?
|
Atrial Fibrillation | 5 | 2023 | 4533 | 0.350 |
Why?
|
Protein Kinase Inhibitors | 2 | 2016 | 5470 | 0.350 |
Why?
|
Inflammation Mediators | 1 | 2017 | 1945 | 0.340 |
Why?
|
Indoles | 2 | 2014 | 1856 | 0.330 |
Why?
|
Kidney Diseases | 1 | 2019 | 2131 | 0.330 |
Why?
|
Interleukin-6 | 1 | 2017 | 3216 | 0.320 |
Why?
|
Platelet Aggregation | 4 | 2017 | 806 | 0.320 |
Why?
|
Proportional Hazards Models | 8 | 2019 | 12412 | 0.310 |
Why?
|
Kaplan-Meier Estimate | 5 | 2017 | 6748 | 0.310 |
Why?
|
Plaque, Atherosclerotic | 1 | 2017 | 1376 | 0.300 |
Why?
|
Warfarin | 1 | 2015 | 1456 | 0.300 |
Why?
|
Recurrence | 5 | 2018 | 8250 | 0.290 |
Why?
|
Stents | 4 | 2022 | 3206 | 0.280 |
Why?
|
Women's Health | 1 | 2015 | 1934 | 0.280 |
Why?
|
Genome-Wide Association Study | 10 | 2022 | 11958 | 0.280 |
Why?
|
Creatinine | 4 | 2022 | 1898 | 0.270 |
Why?
|
Genetic Pleiotropy | 2 | 2016 | 180 | 0.270 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2017 | 1727 | 0.270 |
Why?
|
Disease Management | 1 | 2016 | 2527 | 0.260 |
Why?
|
Diabetes Mellitus | 2 | 2022 | 5468 | 0.250 |
Why?
|
Coronary Thrombosis | 2 | 2019 | 489 | 0.250 |
Why?
|
Renal Insufficiency | 2 | 2022 | 805 | 0.250 |
Why?
|
Prognosis | 13 | 2023 | 29161 | 0.250 |
Why?
|
Troponin T | 3 | 2016 | 751 | 0.250 |
Why?
|
Evidence-Based Medicine | 2 | 2015 | 3684 | 0.240 |
Why?
|
Health Status Disparities | 1 | 2015 | 1733 | 0.240 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2021 | 11026 | 0.230 |
Why?
|
Drug Interactions | 3 | 2013 | 1454 | 0.230 |
Why?
|
Subtilisins | 1 | 2022 | 89 | 0.230 |
Why?
|
N-Acetylgalactosaminyltransferases | 1 | 2022 | 71 | 0.220 |
Why?
|
Sex Factors | 4 | 2021 | 10658 | 0.220 |
Why?
|
Venous Thrombosis | 2 | 2022 | 1219 | 0.220 |
Why?
|
Sleep | 1 | 2017 | 4219 | 0.220 |
Why?
|
Acute Kidney Injury | 1 | 2014 | 1892 | 0.210 |
Why?
|
Multivariate Analysis | 6 | 2017 | 12476 | 0.210 |
Why?
|
Ceramides | 1 | 2022 | 195 | 0.210 |
Why?
|
Anticoagulants | 2 | 2022 | 4349 | 0.200 |
Why?
|
Subtilisin | 1 | 2020 | 11 | 0.200 |
Why?
|
Growth Differentiation Factor 15 | 2 | 2023 | 162 | 0.190 |
Why?
|
Dose-Response Relationship, Drug | 7 | 2021 | 11267 | 0.190 |
Why?
|
Databases, Factual | 1 | 2015 | 7841 | 0.180 |
Why?
|
Scavenger Receptors, Class B | 1 | 2018 | 81 | 0.180 |
Why?
|
Drug Therapy, Combination | 5 | 2022 | 6534 | 0.180 |
Why?
|
Venous Thromboembolism | 2 | 2022 | 1575 | 0.180 |
Why?
|
Myocardium | 1 | 2012 | 4942 | 0.180 |
Why?
|
Serine Proteinase Inhibitors | 1 | 2020 | 181 | 0.180 |
Why?
|
Hospitalization | 5 | 2018 | 9773 | 0.170 |
Why?
|
Oxytocin | 1 | 2022 | 373 | 0.170 |
Why?
|
Incidence | 5 | 2021 | 20648 | 0.170 |
Why?
|
Interleukin-13 Receptor alpha1 Subunit | 1 | 2017 | 24 | 0.170 |
Why?
|
Phospholipids | 1 | 2022 | 811 | 0.170 |
Why?
|
Odds Ratio | 4 | 2017 | 9965 | 0.160 |
Why?
|
Postoperative Complications | 1 | 2020 | 15116 | 0.160 |
Why?
|
Antibodies, Monoclonal | 3 | 2022 | 9594 | 0.160 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2022 | 1991 | 0.160 |
Why?
|
Genetic Variation | 3 | 2017 | 6662 | 0.150 |
Why?
|
Drug Administration Schedule | 2 | 2016 | 5034 | 0.150 |
Why?
|
Adrenomedullin | 1 | 2016 | 87 | 0.150 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 2019 | 395 | 0.150 |
Why?
|
Pregnancy-Associated Plasma Protein-A | 1 | 2016 | 65 | 0.150 |
Why?
|
C-Reactive Protein | 4 | 2016 | 3711 | 0.150 |
Why?
|
Quantitative Trait, Heritable | 1 | 2019 | 557 | 0.140 |
Why?
|
Withholding Treatment | 1 | 2020 | 585 | 0.140 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2019 | 817 | 0.140 |
Why?
|
Troponin I | 3 | 2013 | 634 | 0.140 |
Why?
|
Glycopeptides | 1 | 2016 | 220 | 0.140 |
Why?
|
Models, Biological | 1 | 2012 | 9885 | 0.140 |
Why?
|
Biphenyl Compounds | 1 | 2019 | 902 | 0.140 |
Why?
|
Neutrophils | 1 | 2008 | 3798 | 0.130 |
Why?
|
Atrial Natriuretic Factor | 1 | 2016 | 398 | 0.130 |
Why?
|
Diabetic Nephropathies | 1 | 2022 | 1038 | 0.130 |
Why?
|
Placebos | 2 | 2021 | 1730 | 0.130 |
Why?
|
Drug Monitoring | 1 | 2021 | 935 | 0.130 |
Why?
|
Myocardial Ischemia | 2 | 2016 | 2138 | 0.130 |
Why?
|
Placebo Effect | 1 | 2019 | 593 | 0.130 |
Why?
|
Risk | 3 | 2019 | 9770 | 0.130 |
Why?
|
Simvastatin | 1 | 2017 | 359 | 0.130 |
Why?
|
Quantitative Trait Loci | 2 | 2019 | 1981 | 0.130 |
Why?
|
Obesity | 3 | 2022 | 12256 | 0.130 |
Why?
|
Immune System Diseases | 1 | 2016 | 265 | 0.120 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2011 | 1483 | 0.120 |
Why?
|
Galectins | 1 | 2016 | 249 | 0.120 |
Why?
|
Chest Pain | 2 | 2013 | 1107 | 0.120 |
Why?
|
Stroke Volume | 2 | 2006 | 4593 | 0.120 |
Why?
|
Chi-Square Distribution | 2 | 2017 | 3558 | 0.120 |
Why?
|
Clinical Trials as Topic | 5 | 2021 | 7983 | 0.120 |
Why?
|
Predictive Value of Tests | 6 | 2011 | 15245 | 0.120 |
Why?
|
Aged, 80 and over | 10 | 2021 | 58457 | 0.120 |
Why?
|
Peroxidase | 1 | 2016 | 619 | 0.120 |
Why?
|
Proprotein Convertases | 1 | 2013 | 98 | 0.120 |
Why?
|
Language | 1 | 2021 | 1260 | 0.110 |
Why?
|
Genetic Association Studies | 2 | 2019 | 2718 | 0.110 |
Why?
|
Dyslipidemias | 1 | 2020 | 849 | 0.110 |
Why?
|
Erythropoiesis | 1 | 2016 | 710 | 0.110 |
Why?
|
Pulmonary Embolism | 2 | 2022 | 2361 | 0.110 |
Why?
|
Time Factors | 6 | 2020 | 40979 | 0.110 |
Why?
|
Bone Density Conservation Agents | 1 | 2019 | 797 | 0.110 |
Why?
|
ROC Curve | 4 | 2008 | 3526 | 0.110 |
Why?
|
Clinical Enzyme Tests | 1 | 2011 | 118 | 0.110 |
Why?
|
Protein Precursors | 1 | 2016 | 1193 | 0.110 |
Why?
|
Hypoglycemic Agents | 2 | 2021 | 2779 | 0.110 |
Why?
|
Patient Participation | 1 | 2021 | 1477 | 0.110 |
Why?
|
Kidney | 3 | 2022 | 6911 | 0.110 |
Why?
|
Genetic Loci | 2 | 2022 | 2613 | 0.100 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2019 | 15597 | 0.100 |
Why?
|
Logistic Models | 4 | 2017 | 13600 | 0.100 |
Why?
|
Fibrinolytic Agents | 2 | 2013 | 2121 | 0.100 |
Why?
|
Cardiology | 1 | 2021 | 1643 | 0.100 |
Why?
|
Treatment Failure | 1 | 2016 | 2675 | 0.090 |
Why?
|
Energy Intake | 1 | 2017 | 2154 | 0.090 |
Why?
|
Data Mining | 1 | 2015 | 543 | 0.090 |
Why?
|
Phospholipases A2 | 2 | 2007 | 205 | 0.090 |
Why?
|
Analysis of Variance | 1 | 2018 | 6521 | 0.090 |
Why?
|
Postoperative Hemorrhage | 1 | 2013 | 415 | 0.090 |
Why?
|
Adipose Tissue | 1 | 2021 | 3244 | 0.090 |
Why?
|
Cat Diseases | 1 | 2008 | 38 | 0.090 |
Why?
|
Urinary Calculi | 1 | 2008 | 81 | 0.090 |
Why?
|
Genetic Predisposition to Disease | 3 | 2019 | 17420 | 0.090 |
Why?
|
Oxalates | 1 | 2008 | 103 | 0.090 |
Why?
|
Bifidobacterium | 1 | 2008 | 104 | 0.080 |
Why?
|
Cardiomyopathies | 1 | 2020 | 1840 | 0.080 |
Why?
|
Receptors, Cell Surface | 2 | 2008 | 2917 | 0.080 |
Why?
|
Dog Diseases | 1 | 2008 | 135 | 0.080 |
Why?
|
Liver Cirrhosis | 1 | 2018 | 1754 | 0.080 |
Why?
|
Aortic Valve Stenosis | 1 | 2020 | 1856 | 0.080 |
Why?
|
Leukocytes | 1 | 2016 | 2102 | 0.080 |
Why?
|
Lactobacillus | 1 | 2008 | 179 | 0.080 |
Why?
|
Serine Endopeptidases | 1 | 2013 | 1135 | 0.080 |
Why?
|
Research Design | 2 | 2015 | 5871 | 0.080 |
Why?
|
Diagnostic Techniques, Cardiovascular | 1 | 2008 | 157 | 0.080 |
Why?
|
Acute Disease | 3 | 2007 | 7165 | 0.080 |
Why?
|
Necrosis | 1 | 2011 | 1650 | 0.080 |
Why?
|
Ventricular Function, Left | 1 | 2020 | 3435 | 0.080 |
Why?
|
Propensity Score | 1 | 2013 | 1736 | 0.080 |
Why?
|
Erythrocytes | 1 | 2016 | 2421 | 0.080 |
Why?
|
Diuretics | 1 | 2009 | 584 | 0.080 |
Why?
|
Liver | 1 | 2022 | 7627 | 0.080 |
Why?
|
Disease-Free Survival | 1 | 2017 | 7039 | 0.080 |
Why?
|
Spironolactone | 1 | 2009 | 368 | 0.070 |
Why?
|
Area Under Curve | 2 | 2008 | 1692 | 0.070 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2009 | 646 | 0.070 |
Why?
|
Syndrome | 2 | 2017 | 3200 | 0.070 |
Why?
|
Cerebrovascular Disorders | 1 | 2013 | 1510 | 0.070 |
Why?
|
Energy Metabolism | 1 | 2017 | 2976 | 0.070 |
Why?
|
Epidemiologic Methods | 2 | 2008 | 1366 | 0.070 |
Why?
|
Coronary Angiography | 2 | 2008 | 4412 | 0.070 |
Why?
|
Glucose | 1 | 2017 | 4303 | 0.070 |
Why?
|
Probiotics | 1 | 2008 | 342 | 0.070 |
Why?
|
Survival Rate | 2 | 2018 | 13243 | 0.070 |
Why?
|
Genotype | 2 | 2016 | 12924 | 0.070 |
Why?
|
Enzymes | 1 | 2006 | 276 | 0.070 |
Why?
|
Pyrrolidines | 1 | 2006 | 346 | 0.060 |
Why?
|
Follow-Up Studies | 5 | 2014 | 39257 | 0.060 |
Why?
|
Leukocyte Count | 1 | 2008 | 1665 | 0.060 |
Why?
|
Alanine | 1 | 2006 | 597 | 0.060 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2009 | 1229 | 0.060 |
Why?
|
Data Interpretation, Statistical | 1 | 2013 | 2705 | 0.060 |
Why?
|
Emergency Service, Hospital | 6 | 2008 | 7508 | 0.060 |
Why?
|
Reproducibility of Results | 1 | 2021 | 19513 | 0.060 |
Why?
|
Liver Diseases | 1 | 2011 | 1255 | 0.060 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2013 | 1486 | 0.060 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2007 | 713 | 0.060 |
Why?
|
Infusions, Subcutaneous | 1 | 2021 | 45 | 0.060 |
Why?
|
Inflammation | 2 | 2012 | 10130 | 0.050 |
Why?
|
Sensitivity and Specificity | 2 | 2007 | 14892 | 0.050 |
Why?
|
Adult | 8 | 2022 | 212408 | 0.050 |
Why?
|
Administration, Intranasal | 1 | 2022 | 462 | 0.050 |
Why?
|
Age Factors | 2 | 2017 | 18787 | 0.050 |
Why?
|
Disease Progression | 1 | 2017 | 13287 | 0.050 |
Why?
|
Body Mass Index | 1 | 2017 | 12514 | 0.050 |
Why?
|
Uromodulin | 1 | 2019 | 49 | 0.050 |
Why?
|
Gene Frequency | 2 | 2017 | 3713 | 0.050 |
Why?
|
Antihypertensive Agents | 1 | 2009 | 2057 | 0.050 |
Why?
|
Healthcare Disparities | 1 | 2015 | 3031 | 0.050 |
Why?
|
Protein Disulfide-Isomerases | 1 | 2020 | 197 | 0.040 |
Why?
|
Niacin | 1 | 2019 | 114 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2020 | 377 | 0.040 |
Why?
|
Lung Diseases | 1 | 2008 | 1898 | 0.040 |
Why?
|
United States | 3 | 2022 | 67744 | 0.040 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2020 | 621 | 0.040 |
Why?
|
Inheritance Patterns | 1 | 2019 | 344 | 0.040 |
Why?
|
Child, Preschool | 1 | 2020 | 41197 | 0.040 |
Why?
|
Kidney Function Tests | 1 | 2019 | 701 | 0.040 |
Why?
|
Carbohydrate Metabolism | 1 | 2017 | 283 | 0.040 |
Why?
|
Allelic Imbalance | 1 | 2016 | 77 | 0.040 |
Why?
|
Animals | 7 | 2022 | 170675 | 0.040 |
Why?
|
Erythrocyte Indices | 1 | 2016 | 149 | 0.040 |
Why?
|
Algorithms | 1 | 2016 | 13698 | 0.030 |
Why?
|
Blood Cell Count | 1 | 2016 | 419 | 0.030 |
Why?
|
Osteoporotic Fractures | 1 | 2019 | 375 | 0.030 |
Why?
|
Hematocrit | 1 | 2016 | 638 | 0.030 |
Why?
|
Registries | 2 | 2022 | 8057 | 0.030 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2020 | 1124 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 2012 | 7465 | 0.030 |
Why?
|
Homozygote | 1 | 2019 | 1845 | 0.030 |
Why?
|
Mendelian Randomization Analysis | 1 | 2020 | 891 | 0.030 |
Why?
|
Cross-Over Studies | 2 | 2011 | 2004 | 0.030 |
Why?
|
Smoking | 1 | 2011 | 8940 | 0.030 |
Why?
|
Microfilament Proteins | 1 | 2020 | 1210 | 0.030 |
Why?
|
Muscle Proteins | 1 | 2020 | 1234 | 0.030 |
Why?
|
Interleukin-4 | 1 | 2017 | 1153 | 0.030 |
Why?
|
Platelet Count | 1 | 2016 | 794 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2022 | 1030 | 0.030 |
Why?
|
Quality Control | 1 | 2016 | 869 | 0.030 |
Why?
|
Drug Resistance | 1 | 2019 | 1611 | 0.030 |
Why?
|
Prospective Studies | 4 | 2018 | 51252 | 0.030 |
Why?
|
Spinal Fractures | 1 | 2019 | 688 | 0.030 |
Why?
|
Internationality | 1 | 2018 | 994 | 0.030 |
Why?
|
Survival Analysis | 1 | 2006 | 10528 | 0.030 |
Why?
|
Europe | 1 | 2019 | 3330 | 0.030 |
Why?
|
Leadership | 1 | 2021 | 1343 | 0.030 |
Why?
|
Cytochrome P-450 CYP1A2 | 1 | 2011 | 71 | 0.030 |
Why?
|
Hip Fractures | 1 | 2019 | 885 | 0.030 |
Why?
|
Cohort Studies | 3 | 2018 | 39911 | 0.030 |
Why?
|
Weight Loss | 1 | 2022 | 2501 | 0.030 |
Why?
|
Triglycerides | 1 | 2019 | 2592 | 0.030 |
Why?
|
Chromosome Mapping | 1 | 2019 | 4824 | 0.020 |
Why?
|
Drosophila | 1 | 2017 | 1472 | 0.020 |
Why?
|
Hemoglobins | 1 | 2016 | 1504 | 0.020 |
Why?
|
Critical Illness | 1 | 2022 | 2532 | 0.020 |
Why?
|
Risk Reduction Behavior | 1 | 2016 | 1118 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2020 | 2994 | 0.020 |
Why?
|
Fractures, Bone | 1 | 2019 | 1883 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2017 | 6852 | 0.020 |
Why?
|
Cats | 1 | 2008 | 1037 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2020 | 21809 | 0.020 |
Why?
|
Bone Density | 1 | 2019 | 3424 | 0.020 |
Why?
|
Blood Urea Nitrogen | 1 | 2006 | 198 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2022 | 13621 | 0.020 |
Why?
|
Heart Murmurs | 1 | 2006 | 96 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2020 | 5127 | 0.020 |
Why?
|
Genomics | 1 | 2021 | 5338 | 0.020 |
Why?
|
Medicare | 1 | 2022 | 5776 | 0.020 |
Why?
|
Mortality | 1 | 2016 | 2790 | 0.020 |
Why?
|
Dogs | 1 | 2008 | 4043 | 0.020 |
Why?
|
Systole | 1 | 2006 | 992 | 0.020 |
Why?
|
Proteins | 1 | 2017 | 6161 | 0.010 |
Why?
|
Gastrointestinal Tract | 1 | 2008 | 825 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2017 | 15225 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 23441 | 0.010 |
Why?
|
Phenotype | 1 | 2019 | 16395 | 0.010 |
Why?
|
African Americans | 1 | 2016 | 5024 | 0.010 |
Why?
|
Pregnancy | 1 | 2021 | 27334 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2018 | 15981 | 0.010 |
Why?
|
Point-of-Care Systems | 1 | 2007 | 1125 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2017 | 22868 | 0.010 |
Why?
|
Body Weight | 1 | 2008 | 4689 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 2008 | 8592 | 0.010 |
Why?
|
Linear Models | 1 | 2007 | 5982 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2007 | 8913 | 0.010 |
Why?
|
Heart Rate | 1 | 2006 | 4098 | 0.010 |
Why?
|
Signal Transduction | 1 | 2017 | 23954 | 0.010 |
Why?
|
Rats | 1 | 2008 | 25068 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2019 | 72619 | 0.010 |
Why?
|
Young Adult | 1 | 2017 | 56237 | 0.010 |
Why?
|
Mice | 1 | 2017 | 80995 | 0.010 |
Why?
|
Blood Pressure | 1 | 2006 | 8570 | 0.010 |
Why?
|
Adolescent | 1 | 2017 | 85136 | 0.010 |
Why?
|